Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Therapy for hyperglycemia, related disorders and erectile dysfunction

A technology for fatty acid oxidation and hyperglycemia, which is applied in the field of fatty acid oxidation inhibitors for the treatment of hyperglycemia and related diseases, and can solve the problem that the therapy is not suitable for patients

Inactive Publication Date: 2010-05-05
SYMCOPEIA
View PDF61 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, these types of therapies are not suitable for all patients, as phosphodiesterase 5 inhibitors are contraindicated in patients on organic nitrates and are ineffective if the patient has impaired NO production in the corpus cavernosum

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Therapy for hyperglycemia, related disorders and erectile dysfunction
  • Therapy for hyperglycemia, related disorders and erectile dysfunction
  • Therapy for hyperglycemia, related disorders and erectile dysfunction

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0043]Existing first-line therapies for the treatment of hyperglycemia and T2DM focus on lowering glucose levels (eg, as predicted by a reduction in %HbA1c). Since patients with hyperglycemia and T2DM are at increased risk of morbidity and mortality due to life-threatening sequelae such as T2DM-related cardiovascular disease, retinopathy, nephropathy, and neuropathy, reduction of the risk of this disease may be sought after administration of glucose-lowering therapy adjunctive therapy (eg, lipid-lowering agents, antihypertensives, antianginal agents). Addition of adjuvant therapy may reduce morbidity and mortality in patients with hyperglycemia or T2DM due to, for example, cardiovascular disease. However, other than its effect on hyperglycemia, there is currently no first-line therapy that effectively lowers glucose levels and also reduces the occurrence of life-threatening sequelae of hyperglycemia and T2DM, or reduces - associated cardiovascular disease, retinopathy, nephro...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a methods, compositions and kits for treating hyperglycemia and related disorders, such as type 2 diabetes mellitus, impaired glucose tolerance, diabetic retinopathy, diabetic nephropathy and diabetic neuropathy, and to methods, compositions and kits for treating erectile dysfunction. The methods comprise administering an inhibitor of fatty acid oxidation to a subject in need thereof. In some embodiments, trimetazidine and metformin or a phosphodiesterase 5 inhibitor are administered.

Description

[0001] related application [0002] This application claims the benefit of priority to US Provisional Application No. 60 / 905,934, filed March 9, 2007, the entire teachings of which are incorporated herein by reference. Background of the invention [0003] Type 2 diabetes (T2DM), the most common form of diabetes, occurs when the body does not produce sufficient amounts of insulin, a hormone that causes cells to take up glucose from the blood, or when cells resist the biological effects of insulin. As a result, cells are deprived of their basic energy source, glucose, and glucose levels in the blood accumulate to pathological levels. T2DM has reached pandemic levels, affecting more than 150 million people worldwide. The prevalence of the disease is expected to increase to 300 million people by 2025. Although weight control has the potential to reduce this pandemic, increased availability of low-cost / high-calorie foods and sedentary lifestyles have fueled obesity and subsequent...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61P3/10A61K31/00A61K31/155A61K31/495A61K45/06A61P15/10
CPCA61K31/495A61K31/155A61K45/06A61P15/10A61P3/10A61K2300/00A61K31/00
Inventor 里奥·J·赛蒙
Owner SYMCOPEIA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com